The Conversation (0)
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847. There is no cost or financial obligation to you.
Squarespace, Inc. (NYSE – SQSP)
Under the terms of the agreement, Squarespace will be acquired by Permira for $44.00 per share in cash representing a transaction valued at over $6.6 billion on an equity value basis and approximately $6.9 billion on an enterprise value basis. The investigation concerns whether the Squarespace Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration offers fair value to the Company's shareholders.
Additional information can be found at https://www.brodskysmith.com/cases/squarespace-inc-nyse-sqsp/ .
PlayAGS, Incorporated (NYSE – AGS)
Under the terms of the agreement, AGS will be acquired by affiliates of Brightstar Capital Partners ("Brightstar") for $12.50 per share in cash. The investigation concerns whether the AGS Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration offers fair value to the Company's shareholders.
Additional information can be found at https://www.brodskysmith.com/cases/playags-incorporated-nyse-ags/ .
HashiCorp Inc. (Nasdaq – HCP)
Under the terms of the agreement, HashiCorp will be acquired by IBM (NYSE – IBM). IBM will acquire all outstanding shares of HashiCorp common stock for $35.00 per share in cash, for an enterprise value of $6.4 billion. The investigation concerns whether the HashiCorp Group Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether IBM is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/hashicorp-inc-nasdaq-hcp/ .
Deciphera Pharmaceuticals, Inc. (Nasdaq – DCPH)
Under the terms of the agreement, Deciphera will be acquired by ONO Pharmaceutical Co., Ltd. ("ONO"). ONO will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash, for a total equity value of $2.4 billion. The investigation concerns whether the Deciphera Group Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether ONO is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/deciphera-pharmaceuticals-inc-nasdaq-dcph/ .
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
